Epidemiology of Bladder Cancer

Hematology/Oncology Clinics of North America

Volumn 29, Issue 2, 2015, Pages 177-189

  Malats, Núria ^a   Real, Francisco X ^a,b  

^a Structural Biology and Biocomputing Programme   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Arsenic; Bladder cancer; Genetic susceptibility; Incidence and prevalence; Occupational risk factors; Smoking; Urothelium

Indexed keywords

ARSENIC; CHLORNAPHAZINE; CYCLOPHOSPHAMIDE; GLUTATHIONE TRANSFERASE M1; PHENACETIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

BK VIRUS; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COSTELLO SYNDROME; CYSTITIS; CYTOMEGALOVIRUS; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DISINFECTION; ERCC2 GENE; FAMILY HISTORY; FLUID INTAKE; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GSTM1 GENE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MUSCLE INVASIVE BLADDER CANCER; NAT2 GENE; NBN GENE; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PAPILLOMAVIRIDAE; PATIENT CARE; PHYSICAL ACTIVITY; POLYPOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINOBLASTOMA; REVIEW; SCHISTOSOMIASIS HAEMATOBIA; SMOKING; SMOKING CESSATION; URINARY TRACT INFECTION; URINE PH; XPC GENE; ANIMAL; INCIDENCE; PREVALENCE; RISK FACTOR; URINARY BLADDER NEOPLASMS;

ANIMALS; HUMANS; INCIDENCE; PREVALENCE; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84933512074     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.10.001     Document Type: Review

References (71)

1. Ferlay J., Soerjomataram I., Ervik M., et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet] 2013, International Agency for Research on Cancer, Lyon (France), Available at:, Accessed October 13, 2014. http://globocan.iarc.fr.
2. Bray F., Ren J.S., Masuyer E., et al. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013, 132:1133-1145.
3. Chavan S., Bray F., Lortet-Tieulent J., et al. International variations in bladder cancer incidence and mortality. Eur Urol 2014, 66:59-73.
4. Available at: . Accessed August 4, 2014. http://seer.cancer.gov/statfacts/html/urinb.html.
5. Silverman D., Devesa S.S., Morore L.E., Rothman N. Bladder cancer. Cancer epidemiology and prevention 2006, 1101-1127. Oxford University Press, New York. D. Schottenfeld, J.F. Fraumeni (Eds.).
6. Svatek R.S., Hollenbeck B.K., Holmäng S., et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014, 66(2):253-262.
7. Sjödahl G., Lauss M., Lövgren K., et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012, 18:3377-3386.
8. Zhang Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. JEnviron Sci Health C Environ Carcinog Ecotoxicol Rev 2013, 31:287-304.
9. Shariat S.F., Sfakianos J.P., Droller M.J., et al. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010, 105:300-308.
10. Freedman N.D., Silverman D.T., Hollenbeck A.R., et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011, 306:737-745.
11. Samanic C., Kogevinas M., Dosemeci M., et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 2006, 15:1348-1354.
12. Delclos G.L., Lerner S.P. Occupational risk factors. Scand J Urol Nephrol Suppl 2008, 218:58-63.
13. Reulen R.C., Kellen E., Buntinx F., et al. Ameta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl 2008, 218:64-78.
14. Rota M., Bosetti C., Boccia S., et al. Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to 2014. Arch Toxicol 2014, [Epub ahead of print].
15. Saint-Jacques N., Parker L., Brown P., et al. Arsenic in drinking water and urinary tract cancers: a systematic review of 30 years of epidemiological evidence. Environ Health 2014, 13:44.
16. Murta-Nascimento C., Schmitz-Dräger B.J., Zeegers M.P., et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 2007, 25:285-295.
17. Franklyn J.A., Maisonneuve P., Sheppard M., et al. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1999, 353:2111-2115.
18. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. NEngl J Med 2000, 343:78-85.
19. Lu Y., Ek W.E., Whiteman D., et al. Most common 'sporadic' cancers have a significant germline genetic component. Hum Mol Genet 2014, 23(22):6112-6118.
20. García-Closas M., Malats N., Silverman D., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005, 366:649-659.
21. Marcus P.M., Vineis P., Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000, 10:115-122.
22. Moore L.E., Baris D.R., Figueroa J.D., et al. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 2011, 32:182-189.
23. Wang M., Chu H., Lv Q., et al. Cumulative effect of genome-wide association study-identified genetic variants for bladder cancer. Int J Cancer 2014, 135(11):2653-2660.
24. McDonagh E.M., Boukouvala S., Aklillu E., et al. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics 2014, 4:409-425.
25. Pelucchi C., La Vecchia C. Alcohol, coffee, and bladder cancer risk: a review of epidemiological studies. Eur J Cancer Prev 2009, 18:62-68.
26. Zhou J., Kelsey K.T., Giovannucci E., et al. Fluid intake and risk of bladder cancer in the Nurses' Health Studies. Int J Cancer 2014, 135:1229-1237.
27. Michaud D.S., Kogevinas M., Cantor K.P., et al. Total fluid and water consumption and the joint effect of exposure to disinfection by-products on risk of bladder cancer. Environ Health Perspect 2007, 115:1569-1572.
28. Turati F., Pelucchi C., Galeone C., et al. Personal hair dye use and bladder cancer: a meta-analysis. Ann Epidemiol 2014, 24:151-159.
29. Keimling M., Behrens G., Schmid D., et al. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer 2014, 110:1862-1870.
30. Amaral A.F., Méndez-Pertuz M., Muñoz A., et al. Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. JNatl Cancer Inst 2012, 104:1897-1904.
31. Steinmaus C.M., Nuñez S., Smith A.H. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000, 151:693-702.
32. Villanueva C.M., Cantor K.P., Grimalt J.O., et al. Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. Am J Epidemiol 2007, 165:148-156.
33. Costet N., Villanueva C.M., Jaakkola J.J., et al. Water disinfection by-products and bladder cancer: is there a European specificity? A pooled and meta-analysis of European case-control studies. Occup Environ Med 2011, 68:379-385.
34. Michaud D.S. Chronic inflammation and bladder cancer. Urol Oncol 2007, 25:260-268.
35. Robles C., Viscidi R., Malats N., et al. Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study. Int J Cancer 2013, 133:587-603.
36. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507:315-322.
37. Alguacil J., Kogevinas M., Silverman D., et al. Urinary pH, cigarette smoking, and bladder cancer risk. Carcinogenesis 2011, 32:843-847.
38. Zhu Z., Wang X., Shen Z., et al. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer 2013, 13:310.
39. Esposito K., Chiodini P., Colao A., et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012, 35:2402-2411.
40. Dietrich K., Demidenko E., Schned A., et al. Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. Eur J Cancer 2011, 47:592-599.
41. Weibull C.E., Eloranta S., Altman D., et al. Childbearing and the risk of bladder cancer: a nationwide population-based cohort study. Eur Urol 2013, 63:733-738.
42. Hsu I., Vitkus S., Da J., et al. Role of oestrogen receptors in bladder cancer development. Nat Rev Urol 2013, 10(6):317-326.
43. Kabat G.C., Kim M.Y., Luo J., et al. Menstrual and reproductive factors and exogenous hormone use and risk of transitional cell bladder cancer in postmenopausal women. Eur J Cancer Prev 2013, 22:409-416.
44. Daugherty S.E., Lacey J.V., Pfeiffer R.M., et al. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP diet and health study. Int J Cancer 2013, 133:462-472.
45. Dietrich K., Demidenko E., Schned A., et al. Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. Eur J Cancer 2011, 47:592-599.
46. Fortuny J., Kogevinas M., Garcia-Closas M., et al. Use of analgesics and NSAIDs, genetic predisposition and bladder cancer risk in Spain. Cancer Epidem Biomark Prev 2006, 15:1696-1702.
47. Daugherty S.E., Pfeiffer R.M., Sigurdson A.J., et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 2011, 173:721-730.
48. Bosetti C., Rosato V., Buniato D., et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013, 18:148-156.
49. Kostapanos M.S., Elisaf M.S., Mikhailidis D.P. Pioglitazone and cancer: angel or demon?. Curr Pharm Des 2013, 19:4913-4929.
50. Franciosi M., Lucisano G., Lapice E., et al. Metformin therapy and risk of cancerin patients with type 2 diabetes: systematic review. PLoS One 2013, 8. e71583.
51. Hemminki K., Bermejo J.L., Ji J., et al. Familial bladder cancer and the related genes. Curr Opin Urol 2011, 21:386-392.
52. Murta-Nascimento C., Silverman D.T., Kogevinas M., et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?. Cancer Epidemiol Biomarkers Prev 2007, 16:1595-1600.
53. Aben K.K., Witjes J.A., Schoenberg M.P., et al. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002, 98:274-278.
54. Kratz C.P., Rapisuwon S., Reed H., et al. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011, 157C:83-89.
55. Win A.K., Lindor N.M., Young J.P., et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 2012, 104:1363-1372.
56. Skeldon S.C., Semotiuk K., Aronson M., et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 2013, 63:379-385.
57. Marees T., Moll A.C., Imhof S.M., et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008, 100:1771-1779.
58. Vogt S., Jones N., Christian D., et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009, 137:1976-1985.
59. Stern M.C., Lin J., Figueroa J.D., et al. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res 2009, 69:6857-6864.
60. Crivelli J.J., Xylinas E., Kluth L.A., et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014, 65:742-754.
61. García-Closas M., Hein D.W., Silverman D., et al. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 2011, 21:231-236.
62. Tang W., Fu Y.P., Figueroa J.D., et al. Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Hum Mol Genet 2012, 21:1918-1930.
63. Garcia-Closas M., Ye Y., Rothman N., et al. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 2011, 20:4282-4289.
64. Rafnar T., Vermeulen S.H., Sulem P., et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet 2011, 20:4268-4281.
65. Figueroa J.D., Ye Y., Siddiq A., et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 2014, 23:1387-1398.
66. Rafnar T., Sulem P., Thorleifsson G., et al. Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Hum Mol Genet 2014, 23:5545-5557.
67. Kiemeney L.A., Thorlacius S., Sulem P., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008, 40:1307-1312.
68. Rafnar T., Sulem P., Stacey S.N., et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009, 41:221-227.
69. Rothman N., Garcia-Closas M., Chatterjee N., et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010, 42:978-984.
70. Wu X., Ye Y., Kiemeney L.A., et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009, 41:991-995.
71. Kiemeney L.A., Sulem P., Besenbacher S., et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010, 42:415-419.